ep ahead consensu iclr adj ep
shi estim better revenu
profit off-set factor line maintain
ep boost tp greater
evid continu strength underli non-pf busi
revenu cc exceed view post
solid net book-to-bil ex-pf ahead plan net
new busi million also plan million cancel
rate histor averag backlog
convers tick lower oncolog mix
gross margin dip bp greater sg leverag bp
bp better plan help drive ebitda margin expans
bp flow million help fund continu share
repurchas million cash reserv stand million
share rise earth shatter data point
releas guidanc par pre-announce excl
account chang share ralli encourag book
trend repres revenu
impli cc growth underli busi
impress dynam view increment contribut sever
new partnership ep iclr trade discount
cro peer view unwarr ascrib littl
underli busi strength profit capit deploy driver risk
includ shift demand cancellations/win
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
icon public limit compani icon ireland-bas contract
servic pharmaceut biotechnolog medic devic
price feb rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
blue sky valuat iclr assum substanti
new busi win addit project award offset
sizabl cancel increment profit margin expans
pronounc strength spend outsourc demand
grey sky valuat iclr assum greater-
than-expect declin busi largest custom
consolid capit deploy misstep weaken demand
outsourc
healthi btb excl well-receiv investor repres
third consecut quarter btb re-affirmed guid impli
continu strength non-pf organ revenu backlog convers
slightli industri averag
dynam attribut prolong start-up phase certain larger client along
broader impact larger studi matur increas work complex oncolog
project consist recent industri commentari cancel rate flat
quarter lead million vs million
reaffirm guidanc re-affirmed ep guidanc call ep
notabl expect compris revenu
repres current backlog prior year
account updat consist expect accord iclr
updat guidanc includ reimburs expens pass expens
revenu begin servic revenu reimburs revenu
report line item note account chang impact iclr
ep guidanc discuss regard revenu estim refer
revenu updat
charl martineau pm univers toronto figur backlog convers continu impact increas mix complex therapeut area
note industri averag adjust vari definit recognit backlog less aggress depend compani
figur book-to-bil ratio remain rel healthi roughli line industri averag
consist elimin quarterli fluctuat calcul dso use ttm
total revenu servic revenu reimburs revenu weight averag
net receiv bill unbil less prepaid revenu trail five quarter
base calcul iclr ttm dso current stand day line
previou quarter within consid normal rang
day longer term receiv grow slightli sequenti potenti
associ chang contract term larger strateg partner among
factor compar industri averag gener day rang
public trade coverag
gener million cash cash reserv current stand
million net cash million capit deploy prioriti continu
balanc share buyback tuck-in deal opportunist basi could
provid upsid estim
iclr share current trade ep peer group clinic
ascrib littl non-pf prospect acceler well profit
capit deploy driver broadli view iclr well-posit benefit
continu strong fundament across cro industri
forecast iclr net servic revenu increas billion
fuel increas custom diversif contribut clinic
rm mapi group partial off-set cancel ep
forecast predic ebitda margin contribut
share repurchas forecast ep growth predic
revenu growth billion ebitda margin expans bp
iclr share current trade ep estim premium
histor averag target price ep estim better
reflect opportun continu market share gain slightli temper slow
backlog burn diminish contribut profit margin leverag opportun
potenti upsid capit deploy option lowest leverag ratio
cro univers
compani mention price
